{"id":9599,"date":"2018-11-15T12:31:22","date_gmt":"2018-11-15T10:31:22","guid":{"rendered":"https:\/\/latam.patiadiabetes.com\/en\/alianza-la-industria-alimentaria-biotecnologicas-hospitales-crear-soluciones-la-prevencion-la-diabetes-gestacional\/"},"modified":"2020-12-07T18:14:00","modified_gmt":"2020-12-07T16:14:00","slug":"alliance-food-industry-gestational-diabetes","status":"publish","type":"post","link":"https:\/\/latam.patiadiabetes.com\/en\/alliance-food-industry-gestational-diabetes\/","title":{"rendered":"Food industry unites for the first time with biotech companies and hospitals to create solutions in the prevention of gestational diabetes"},"content":{"rendered":"

Food industry unites for the first time with biotech companies and hospitals to create solutions in the prevention of gestational diabetes<\/h1>\n
\n

Led by Patia Europe, the hub of Spanish food companies, tech and biotechnology companies was presented on 14th<\/sup> November, the International Diabetes Day.<\/p>\n<\/blockquote>\n<\/div>

<\/div><\/div><\/div>

Gestational diabetes (GDM), which affects 10% of pregnancies in Spain, is one of the main health problems associated with pregnancy. It is characterized by carbohydrate intolerance, is diagnosed between the 24th and 26th week, and is associated with considerable risks to both the mother and the fetus. So, the challenge is for pregnant women to have access to better evidence of prevention, care, products and education on GDM.<\/p>\n

One in two women with gestational diabetes will develop diabetes 10 years after childbirth. The fetus can have serious health problems such as malformations, respiratory failure, even fetal death. A baby born of a pregnancy with gestational diabetes has a 60% greater chance of developing obesity and type 2 diabetes in the future.<\/p>\n<\/div>

<\/div><\/div><\/div>
\"Industrai<\/h6>\n
<\/h6>\n
<\/h6>\n
<\/h6>\n
<\/h6>\n
<\/h6>\n
<\/h6>\n
<\/h6>\n
<\/h6>\n
<\/h6>\n
Left\u00a0to right: Leire Mendiz\u00e1bal (PATIA Technical Director), Jaime Razkin (PATIA Marketing &\u00a0operations), Ainara Arregui (ANGULAS AGUINAGA R+D Manager\u00a0), Nekane Larburu (VICOMTECH\u00a0Senior Researcher), Goizane Lizarralde (OKIN R+D Director), C\u00e9line Corrignan (OKIN Sales director), Javier Escobal (INIT Group Innovation Director), Roberto \u00c1lvarez ( VICOMTECH Researcher), Ainhoa C. Angoitia (SENDABIO Research Director), Sara Arranz (AZTI Food & Health Senior Researcher).<\/h6>\n<\/div>
<\/div><\/div><\/div>

Products in progress<\/h2>\n<\/div>
<\/div><\/div><\/div>

\"Patia<\/p>\n

The first achievement of this consortium is Patia’s<\/strong> genetic test for the early detection of gestational diabetes. It is a genetic test, named GDMpredict<\/em><\/strong><\/a>, which is a non-invasive, highly specific and sensitive test that determines the risk of developing gestational diabetes during pregnancy. It is a world novelty that allows the detection of gestational diabetes before pregnancy or in the first weeks, well before the current diagnosis which facilitates the prevention of serious complications that gestational diabetes can entail. The test has been developed together with the Biocruces Research Institute<\/strong>, Basque country, Spain.<\/p>\n<\/div>

<\/div><\/div><\/div>

\"GDMpredict<\/p>\n<\/div>